Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism

Korean Journal of Urology

Volumn 52, Issue 11, 2011, Pages 725-735

  Kim, Jin Wook ^a   Moon, Du Geon ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Erectile dysfunction; Hormone replacement therapy; Hypogonadism; Libido; Testosterone

Indexed keywords

ALBUMIN; FOLLITROPIN; LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AGING; ARTICLE; CHEMICAL ANALYSIS; CLINICAL FEATURE; DRUG SAFETY; ERECTILE DYSFUNCTION; ERYTHROCYTOSIS; FLUID RETENTION; GINGIVA DISEASE; GYNECOMASTIA; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LATE ONSET HYPOGONADISM; MALE; NONHUMAN; ONSET AGE; PATIENT MONITORING; PRACTICE GUIDELINE; PROSTATE; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL;

EID: 84255198445     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.11.725     Document Type: Article

References (95)

1. Brown-Sequard CE. Lancet 1889;134:105-6.
2. Feldman HA, Longcope C, Derby C, Johannes C, Araujo AB, Coviello A, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Balitimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Balitimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.
4. Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA. Frailty and the aging male. Aging Male 2005;8:135-40.
5. Morales A, Heaton JPW. Androgen deficiency in the aging male. In: Broderick G, editor. Oral drug therapy of sexual dysfunction. 1st ed. Totowa NJ: Humana Press Inc; 2005; 279-99.
6. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2008;21:1-8.
7. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
8. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
9. Nicolosi A, Buvat J, Glasser DB, Hartmann U, Laumann EO, Gingell C. Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: The global study of sexual attitudes and behaviors. World J Urol 2006;24:423-8.
10. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7.
11. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006;91:2509-13.
12. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, et al. Age related changes in general and sexual health in middle aged and older men: Results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-80.
13. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
14. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999;107:123-36.
15. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, Wilson PW, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119:426-33.
16. Barrett-Connor E, Mueller JE, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:219-23.
17. Nyquist F, Gärdsell P, Sernbo I, Jeppsson JO, Johnell O. Assessment of sex hormones and bone mineral density in relation to occurrence of fracture in men: A prospective population-based study. Bone 1998;22:147-51.
18. Laughlin G, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
19. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-43.
20. Gooren LJ. Diagnostic approach to the aging male. World J Urol 2002;20:17-22.
21. Heinemann L, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new 'aging males' symptoms' rating scale. Aging Male 1999;2:105-14.
22. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42.
23. Morley JE, Perry HM 3rd, Kevorkian R, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:424-9.
24. Handelsman DJ. Testosterone: use, misuse and abuse. Med J Aust 2006;185:436-9.
25. O'Connor DB, Corona G, Forti G, Tajar A, Lee DM, Finn JD, et al. Assessment of sexual health in aging men in Europe: Development and validation of the European Male Ageing Study sexual function questionnaire. J Sex Med 2008;5:1374-85.
26. Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, et al. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. Aging Male 2009;12:77-85.
27. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992;74:623-8.
28. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68.
29. Rosner W, Deakins SM. Testosterone-binding globulins in human plasma: studies on sex distribution and specificity. J Clin Invest 1968;47:2109-16.
30. Khan MS, Knowles BB, Aden DP, Rosner W. Secretion of testosterone-estradiol-binding globulin by a human hepatoma-derived cell line. J Clin Endocrinol Metab 1981;53:448-9.
31. Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC, et al. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 1995;53:567-72.
32. Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W. Sex hormone- binding globulin is synthesized in target cells. J Endocrinol 2002;175:113-20.
33. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009;5:113-21.
34. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007;282:25801-16.
35. Wu D, Gore AC. Changes in androgen receptor, estrogen receptor alpha, and sexual behavior with aging and testosterone in male rats. Horm Behav 2010;58:306-16.
36. Frye CA. Hormonal infliences on seizures: basic neurobiology. Int Rev Neurobiol 2008:83;27-75.
37. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009;12:232-40.
38. Lee HJ, Chang C. Recent advances in androgen receptor action. Cell Mol Life Sci 2003;60:1613-22.
39. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: Contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007;92:3604-10.
40. Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J Urol 2010; 183:2294-9.
41. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813-7.
42. Morley JE, Patrick P, Perry HM 3rd. Evaluation of assays available to measure free testosterone. Metabolism 2002;51:554-9.
43. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
44. Cunningham GR, Toma SM. Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab 2010;96:38-52.
45. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: Can a case be made for a 3-month therapeutic trial? BJU Int 2004;94:1066-70.
46. Morales A, Lunenfeld B; International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5:74-86.
47. Morales A, Spevack M, Emerson L, Kuzmarov I, Casey R, Black A, et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007;10:57-65.
48. Anderson RH, Fleming DE, Rhees RW, Kinghorn E. Relationships between sexual activity, plasma testosterone, and the volume of the sexually dimorphic nucleus of the preoptic area in prenatally stressed and non-stressed rats. Brain Res 1986;370:1-10.
49. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497-501.
50. Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160:815-9.
51. Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proc 2007;82:20-8.
52. Reyes Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med 2007;4:1757-62.
53. Allan CA, Forbes EA, Strauss BJ, McLachlan RI. Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res 2008;20:396-401.
54. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-98.
55. Diaz-Arjonilla M, Schwarcz M, Swerdloff R, Wang C. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res 2008;21:89-98.
56. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004;171:2341-5.
57. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999;281:421-6.
58. Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30: 880-8.
59. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
60. Lugg JA, Rajfer J, González-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-501.
61. Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005;26:182-8.
62. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-16.
63. Rhoden EL, Telöken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002;167:1745-8.
64. Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, et al. Testosterone and sexual activity. J Endocrinol Invest 2005;28(3 Suppl):39-44.
65. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58: 632-8.
66. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530-2.
67. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-7.
68. Chatterjee R, Wood S, McGarrigle HH, Lees WR, Ralph DJ, Neild GH. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care 2004;30:88-90.
69. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.
70. Aversa A, Bruzziches R, Francomano D, Natali M, Lenzi A. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol 2009;1:179-97.
71. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
72. D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007;110:1723-8.
73. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-20.
74. Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology 1995;46:58-61.
75. Liu CC, Huang SP, Li WM, Wang CJ, Chou YH, Li CC, et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 2007;70:677-80.
76. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum ormones and the risk of prostate cancer. Cancer Res 1988;48:3515-7.
77. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Alen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
78. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-61.
79. Sen A, O'Malley K, Wang Z, Raj GV, Defranco DB, Hammes SR. Paxillin regulates androgen-and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010;285:28787-95.
80. Bagatell CJ, Bremner WJ. Androgens in men - uses and abuses. N Engl J Med 1996;334:707-14.
81. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988;9: 181-99.
82. See KL, Søe M, Gluud C. Liver pathology associated with the use of anabolic androgenic steroids. Liver 1992;12:73-9.
83. Matsumoto AM, Sandblom RE, Schene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. 1985;22:713-21.
84. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opinion on Drug Saf 2004;3:599-606.
85. Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003;88:3605-13.
86. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289:72-80.
87. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701.
88. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-93.
89. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-6.
90. Jones RD, Pugh PJ, Jones TH, Channer KS. The vasodilatory action of testosterone: A potassium channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-44.
91. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161: 443-9.
92. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
93. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
94. Farid S, Louis J. The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2. J Obes 2010;2011.
95. Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male 2007;10:139-53.